Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy

被引：0
|
作者：
M. Kalder
I. Kyvernitakis
U. S. Albert
M. Baier-Ebert
P. Hadji
机构：
[1] Philipps University of Marburg,Department of Obstetrics and Gynecology
[2] Krankenhaus Nordwest,Department of Obstetrics and Gynecology
[3] Novartis Pharma GmbH,Clinical & Regulatory Affairs/Biometrics Department
[4] Krankenhaus Nordwest,Department of Bone Oncology, Endocrinology and Reproductive Medicine
来源：
Osteoporosis International | 2015年 / 26卷
关键词：
Bone mineral density; Breast cancer; Osteoporosis; Trabecular bone score; Zoledronic acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 360
页数：7
相关论文
共 50 条
  • [1] Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy
    Kalder, M.
    Kyvernitakis, I.
    Albert, U. S.
    Baier-Ebert, M.
    Hadji, P.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 (01) : 353 - 360
  • [2] Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study
    P. Hadji
    A. Kauka
    M. Ziller
    K. Birkholz
    M. Baier
    M. Muth
    M. Bauer
    Osteoporosis International, 2014, 25 : 1369 - 1378
  • [3] Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study
    Hadji, P.
    Kauka, A.
    Ziller, M.
    Birkholz, K.
    Baier, M.
    Muth, M.
    Bauer, M.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 (04) : 1369 - 1378
  • [4] Effects of Exemestane and Tamoxifen Treatment on Bone Texture Analysis Assessed by TBS in Comparison With Bone Mineral Density Assessed by DXA in Women With Breast Cancer
    Kalder, Matthias
    Hans, Didier
    Kyvernitakis, Ioannis
    Lamy, Olivier
    Bauer, Martina
    Hadji, Peyman
    JOURNAL OF CLINICAL DENSITOMETRY, 2014, 17 (01) : 66 - 71
  • [5] Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial
    Kyvernitakis, Ioannis
    Kann, Peter Herbert
    Thomasius, Friederike
    Hars, Olaf
    Hadji, Peyman
    BONE, 2018, 114 : 109 - 115
  • [6] Effects of Aromatase inhibitors on bone mineral density and trabecular bone score in patients with breast cancer
    Dabbagh, V.
    Shandiz, F. Homaee
    Kermani, A. Taghizadeh
    Javan, F. Nesari
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S465 - S465
  • [7] Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS)
    Kang, Taewook
    Park, Si Young
    Lee, Soon Hyuck
    Park, Jong Hoon
    Suh, Seung Woo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2022, 37 (13)
  • [8] Cancer Treatment-Induced Bone Loss in women with breast cancer
    Hadji, Peyman
    BONEKEY REPORTS, 2015, 4
  • [9] Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: A three-year study
    Popp, Albrecht W.
    Guler, Sabina
    Lamy, Olivier
    Senn, Christoph
    Buffat, Helene
    Perrelet, Romain
    Hans, Didier
    Lippuner, Kurt
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (03) : 449 - 454
  • [10] Zoledronic acid inhibits cancer treatment-induced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatment
    不详
    BREAST, 2005, 14 : S44 - S44
12345